TamoRx is an Auckland-based biotechnology company focussed on developing novel immuno-oncology therapeutics.
TamoRx’s founding inventors have discovered a novel biological mechanism within cells that restricts the immune system from fighting cancer. The research team is focused on developing a new therapy that frees patient’s immune systems from this restriction to increase immune attack on cancer cells within tumours offering a new hope for a broad range of cancer patients. TamoRx is aiming to develop small molecule inhibitors that work both as a single agent and in combination with other treatments, increasing the applicability of immunotherapy for patients.
TamoRx is funded by Brandon Capital’s Brandon BioCatalyst and the University of Auckland Inventors’ Fund, managed by UniServices.
